About

History of Nasodine

Nasodine® Nasal Spray is the product of more than 10 years of pharmaceutical R&D by Firebrick Pharma Ltd, an innovative Australian biopharmaceutical company.

Nasodine has been assessed now in six independently-controlled human clinical trials and its safety and use are supported by a growing list of peer-reviewed publications.

Firebrick Pharma owns several patents covering the unique Nasodine formulation and its use in the treatment and prevention of upper respiratory infections. The Nasodine® trademark is registered internationally by Firebrick Pharma.

  • 2012 Founding

    Firebrick Pharma was founded with the mission to develop a PVP-iodine nasal spray to kill germs in the nose.

  • 2014-2017 Development

    Development commences to create a stable nasal formulation and packaging. International patent granted on the intranasal use of PVP-iodine.

  • 2018-2023 Human Clinical trials

    Phase 1, 2 and 3 human clinical trials show that Nasodine is safe to use in the nose 4 times daily for 5 days.

  • 2024 Nasodine international launch

    Nasodine Nasal Spray becomes available for sale in selected markets, including Singapore.

  • Power of povidone-iodine in a nasal spray

    Shown in laboratory studies to kill all the germs that can cause nasal infections.

  • Commuting and crowds may be hotspots for germs

    When people around you have symptoms, Nasodine can help protect you from other people's germs.

  • The right choice for healthcare professionals

    Backed by 10 years of R&D, proven clinical safety, and published clinical studies.

Take action against nasal germs